PTPRC and infection: At week 2 post-infection and treatment, the lungs from JHU083-treated mice showed a statistically significant 25% higher frequency of CD4+ T-cells (mean = 36.9% of live CD45+) compared to both untreated (mean = 29.5% of live CD45+) and RIF-treated mice (mean = 24.5% of live CD45+) (Fig. 4a).